海思科：HSK39297片上市许可获受理

Group 1 - The core point of the article is that the company, Hisun Pharmaceutical (002653), announced that its subsidiary, Sichuan Hisun Pharmaceutical Co., Ltd., received a "Notice of Acceptance" from the National Medical Products Administration for a new drug application [1] - The drug in question is named HSK39297 tablets, which is intended for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1]